Wharton's Jelly and Exosome Supplier for Little Rock Medspas

How aesthetic practices in the Southeast vet a biologics supplier

Medspas, dermatology practices, and plastic surgery practices generally involve a supervising physician or medical director in reviewing a new biologics supplier, since ordering accounts are restricted to licensed professionals. That review typically covers sourcing documentation, processing description, and any available characterization data before a product is considered for the practice.

Because how a Wharton's jelly or exosome product is regulated depends on the specific intended use, many practices extend this review to outside counsel before finalizing a decision.

Account setup, logistics, and documentation

Precision Biologics verifies ordering accounts against an NPI number before granting access to pricing or lot-specific documentation. Cryopreserved Wharton's jelly products ship overnight on dry ice in validated containers for -80 degree Celsius storage, while lyophilized exosome and Wharton's jelly formats are shelf-stable and ship per the insert supplied with the lot, which can be useful for a practice without ultra-low freezer space.

A certificate of analysis, donor eligibility summary, and lot release record are available to verified accounts for each lot, along with supplier-reported characterization data for exosome products on request.

Confirming supervision and regulatory requirements

Arkansas medspas and aesthetic practices should confirm physician-supervision requirements and medical-director oversight directly with the Arkansas medical board and their own counsel, since these requirements sit outside what any supplier can advise on. Precision Biologics does not advise on clinical use, treatment planning, or product selection for a specific patient.

A peer-to-peer call with physician-level staff is available to review sourcing and documentation questions as part of account setup.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.